Brand Name: Esloric 100
Manufacturer:Ā Square Pharmaceuticals Ltd.
INDICATION
EsloricĀ® is indicated in the management of patients with signs and
symptoms of primary and secondary gout, leukaemia, lymphoma,
malignancies who are receiving cancer therapy which causes elevations of
serum and urinary uric acid levels, recurrent calcium oxalate calculi whose
daily uric acid excretion exceeds 800 mg/day in male and 750 mg/day in
female patients.
DOSAGE AND ADMINISTRATION
Adults:
Mild gout: 200 to 300 mg/day.
Moderately severe tophaceous gout: 400 to 600 mg/day.
The minimal effective dosage is 100 to 200 mg daily and the maximal
recommended dosage is 800 mg daily. To reduce the possibility of flare-up
of acute gouty attacks, it is recommended that the patient start with a low
dose of EsloricĀ® (100 mg daily) and increase at weekly intervals by 100 mg
until a serum uric acid level of 6 mg/day or less is attained but without
exceeding the maximal recommended dosage.
Recurrent calcium oxalate stones: 200 to 300 mg/day.
Children:
Age 6-10 years: In secondary hyperuricemia associated with malignancies
may be given 300 mg EsloricĀ® daily.
Age under 6 years: generally given 150 mg daily.
CONTRAINDICATION AND PRECAUTION
Patients who have developed a severe reaction to allopurinol should not be
restarted the drug.
Allopurinol should be withdrawn immediately when a skin rash or other
evidence or sensitivity occurs. Dosage reduction should be considered in
the presence of severe hepatic or renal disorder.
SIDE EFFECT
The most frequent adverse reaction to allopurinol is skin rash such as,
pruritic maculopapular skin eruptions, sometimes scaly or exfoliative. Some
patients with the most severe reaction, also had fever, chill, arthralgias,
cholestatic jaundice, eosinophilia and mild leukocytosis or leukopenia.
DRUG INTERACTION
Anticoagulant ā Allopurinol prolongs the half life of the anticoagulant,
dicumarol. Diuretic ā Concomitant use of Allopurinol and thiazide diuretics
may contribute to the enhancement of Allopurinol toxicity. Cytotoxic agent ā
Enhanced bone marrow suppression by cyclophosphamide and other
cytotoxic agent has been reported among patients with neoplastic disease.
USE IN PREGNANCY AND LACTATION
There are, however, no adequate or well controlled studies in pregnant
women. This drug should be used during pregnancy only if clearly indicated.
Allopurinol has been found in breast milk, caution should be exercised when
Allopurinol is administered to a lactating mother.
Reviews
There are no reviews yet.